First multi-virus test patented in Singapore

An innovative test developed in Singapore has been patented to address future pandemics. The product will be available in 90 countries. The test, known as a multiple surrogate neutralization test (sVNT), detects the presence of antibodies that can neutralise multiple viruses, offering protection or prevention from the disease. The test functions by employing antibodies present within an individual’s blood sample to impede the virus’s ability to bind to host cells. The test can identify neutralising antibodies against highly pathogenic virus strains, including variants of Sars-CoV-2. It has also been proven effective against viruses such as Ebola, Henipavirus, and other zoonotic diseases. Due to its cell-free approach, the test can be performed more efficiently and safely, without the risks of handling live pathogens.